

# Future of Diabetes Care: Tubeless Insulin Pump Market to Reach \$9.65B by 2031 | DataM Intelligence

*Explore the booming tubeless insulin pump market, projected to reach USD 9.65B by 2031, driven by innovation and rising global diabetes prevalence.*

AUSTIN, TX, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- The [tubeless insulin pump market](#) was valued at USD 2.45 billion in 2023 and is projected to reach approximately USD 9.65 billion by 2031, growing at a compound annual growth rate (CAGR) of 18.74%. With rising demand for smarter and less invasive diabetes management solutions, the market is anticipated to hit USD 2.92 billion in 2024, underscoring the increasing preference for automated and user-friendly insulin delivery systems.



Download Exclusive Sample Report Here: <https://www.datamintelligence.com/download-sample/tubeless-insulin-pumps-market>

“

With a projected CAGR of 18.74% and growth from USD 2.45B in 2023 to USD 9.65B by 2031, tubeless insulin pumps are transforming diabetes care with innovation, ease, and efficiency.”

*DataM Intelligence*

The global tubeless insulin pump market is undergoing a transformation as healthcare systems prioritize more user-friendly and efficient diabetes management solutions. These wearable, wireless devices are gaining popularity due to their ability to simplify insulin delivery without the hassle of tubing, especially among patients seeking comfort, discretion, and convenience.

The upward trajectory is driven by rising global diabetes incidence, a growing elderly population, and a shift toward

digital healthcare technologies. Additionally, increased awareness about the benefits of tubeless

systems like ease of use, reduced skin irritation, and improved lifestyle integration is further accelerating market growth.

## Regional Outlook

### North America

North America dominates the tubeless insulin pump market, with the United States serving as the primary driving force behind the region's growth. High diabetes prevalence, supportive reimbursement frameworks, and a tech-savvy patient base contribute significantly to market dominance. The region also benefits from early adoption of advanced healthcare solutions and strong regulatory support for innovative medical devices.

### Europe

Europe is steadily growing, driven by government initiatives for better diabetes management, aging demographics, and increased healthcare spending. Countries like Germany, France, and the UK are showing strong uptake of tubeless systems, especially as patient education and access to healthcare improve.

### Asia-Pacific

The Asia-Pacific region offers significant growth opportunities, especially in rapidly developing markets such as China and India. Rapid urbanization, changing lifestyles, and improved diagnostic rates are major contributors. Japan, in particular, stands out for its innovation-driven approach and early adoption of advanced medical devices.

## Key Market Players

Insulet Corporation

F. Hoffmann-La Roche Ltd

Debiotech SA

CeQur Corporation

Terumo Corporation

Tandem Diabetes Care, Inc

EOFLOW CO., LTD

Medtrum Technologies Inc

Microtec Medical

## Ascensia Diabetes Care Holdings AG

### Latest News – USA

The United States remains the innovation hub for diabetes technology, with two significant developments in 2024:

In August 2024, Insulet Corporation garnered attention when the FDA approved its Omnipod 5 Automated Insulin Delivery System for use in adults with type 2 diabetes. This marks the first-ever FDA-approved automated system for both type 1 and type 2 diabetes management, opening up a vast new segment of potential users.

Tandem Diabetes Care launched its Tandem Mobi insulin pump earlier this year. Touted as the world's smallest durable automated insulin delivery system, the device offers enhanced portability and a discreet design that caters to active lifestyles. This innovation is expected to capture a growing portion of younger and tech-friendly diabetic patients.

These developments underscore the U.S.'s commitment to expanding access to smart insulin delivery and highlight its pivotal role in global market leadership.

### Latest News – Japan

Japan's healthcare system continues to emphasize technology integration, and the tubeless insulin pump market is a clear beneficiary of this trend:

Terumo Corporation, a homegrown leader in medical devices, remains a key driver of innovation in Japan. Its MEDISAFE WITH insulin patch pump, which received CE Mark approval in 2020, is Japan's only tubing-free solution available to date. Terumo is now exploring broader European market access, bolstering its export and global revenue prospects.

With Japan's aging population and rising diabetes rates, analysts expect the tubeless insulin pump market to reach USD 781 million by 2032, supported by a CAGR of over 13%. Adoption is being further boosted by favorable health policies and growing consumer preference for wearable, intuitive solutions.

Japan is also seeing growing collaborations between technology companies and healthcare providers, signaling an increase in the country's digital health investments and infrastructure for chronic disease management.

### Market Segmentation:

By Type: Insulin Patch Pumps, Traditional Pumps with Disposable Reservoirs.

By Component: Insulin Pump (Pod), Remote Controller.

By Application: Type-1 Diabetes, Type-2 Diabetes.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

## Conclusion

The global tubeless insulin pump market is entering an exciting phase of rapid expansion, backed by innovation, rising demand for ease-of-use medical devices, and broader acceptance among both patients and healthcare providers. With strong footholds in North America and promising growth in regions like Asia-Pacific, especially Japan, the market is expected to remain dynamic over the next decade.

As companies continue to introduce next-gen devices and expand into emerging markets, the future of tubeless insulin pumps looks both inclusive and transformative aimed at improving the quality of life for millions of people living with diabetes.

Stay informed with the latest industry insights-start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Related Reports:

[Insulin Delivery devices Market](#)

[Insulin Pen Market](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/818191349>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

